MCID: SQM006
MIFTS: 74

Squamous Cell Carcinoma

Categories: Rare diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Squamous Cell Carcinoma

MalaCards integrated aliases for Squamous Cell Carcinoma:

Name: Squamous Cell Carcinoma 12 72 49 36 28 14 69
Epidermoid Carcinoma 12 72 49
Carcinoma, Squamous Cell 72 49
Squamous Cell Cancer 12 51
Squamous Cell Carcinoma of the Skin 28
Squamous Cell Carcinoma - Category 69
Malignant Squamous Cell Neoplasm 69
Squamous Cell Carcinoma of Skin 69
Malignant Squamous Cell Tumor 12
Squamous Cell Carcinoma Nos 12
Squamous Cell Epithelioma 12
Squamous Cell Skin Cancer 49
Neoplasms, Squamous Cell 41
Carcinoma Squamous Cell 51
Squamous Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1749
NCIt 46 C2929
KEGG 36 H00040

Summaries for Squamous Cell Carcinoma

NIH Rare Diseases : 49 Squamous cell carcinoma (SCC) is the second most common skin cancer. SCC most often affects individuals who are exposed to large amounts of sunlight. It is typically characterized by a red papule or plaque with a scaly or crusted surface; it may be suspected whenever a small, firm reddish-colored skin lesion, growth or bump appears on the skin, but it may also be a flat growth with a curly and crusted surface. Most often these growths are located on the face, ears, neck, hands and/or arms, but they may occur on the lips, mouth, tongue, genitalia or other area. The most common causes of SCC are radiation from the sun and arsenic exposure. With appropriate treatment, it is usually curable. Last updated: 6/22/2011

MalaCards based summary : Squamous Cell Carcinoma, also known as epidermoid carcinoma, is related to oral squamous cell carcinoma and basaloid squamous cell carcinoma. An important gene associated with Squamous Cell Carcinoma is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Erbitux and Intron A have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and tongue, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A carcinoma that derives from squamous epithelial cells.

Wikipedia : 72 Squamous cell carcinomas, also known as epidermoid carcinoma are a number of different types of cancer... more...

Related Diseases for Squamous Cell Carcinoma

Diseases related to Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 861)
# Related Disease Score Top Affiliating Genes
1 oral squamous cell carcinoma 35.1 CCND1 CDKN2A CTTN EGFR HRAS PTGS2
2 basaloid squamous cell carcinoma 35.0 CDKN2A EGFR TP53
3 lung squamous cell carcinoma 34.9 BRAF EGFR HRAS TP53 TP63
4 squamous cell carcinoma, head and neck 34.9 CCND1 CDKN2A CTTN EGFR ERBB2 GSTP1
5 cervical squamous cell carcinoma 34.8 CDKN2A EGFR SERPINB3 TP53 TP63
6 vulva squamous cell carcinoma 34.7 CDKN2A SERPINB3 TP53
7 bladder squamous cell carcinoma 34.7 CDKN2A PTEN PTGS2 TP53
8 esophagus squamous cell carcinoma 34.6 CCND1 CTTN WWOX
9 squamous cell carcinoma of the larynx 34.6 CDKN2A EGFR TP53
10 bone squamous cell carcinoma 34.6 CDKN2A CTTN TP53
11 skin squamous cell carcinoma 34.5 BRAF HRAS TP53
12 esophageal basaloid squamous cell carcinoma 34.4 EGFR TP53 WWOX
13 tongue squamous cell carcinoma 34.3 CDKN2A DDR2 TP53
14 squamous cell carcinoma of the oropharynx 34.3 CDKN2A TP53
15 tonsil squamous cell carcinoma 34.3 CCND1 CDKN2A
16 esophageal cancer 33.9 CCND1 CDKN2A DLEC1 EGFR ERBB2 GSTP1
17 actinic keratosis 33.4 CDKN2A PTGS2 TP53 TP63
18 oral cancer 33.3 CCND1 CDKN2A EGFR PTGS2 TP53
19 penile cancer 33.3 CCND1 CDKN2A EGFR HRAS TP53
20 adenosquamous carcinoma 33.3 EGFR TP53 TP63
21 adenocarcinoma 33.2 BRAF CCND1 CDKN2A EGFR ERBB2 HRAS
22 nasopharyngeal carcinoma 33.2 CCND1 CDKN2A EGFR HRAS TGFBR2 TP53
23 bladder cancer 33.0 CCND1 CDKN2A EGFR ERBB2 GSTP1 HRAS
24 prostate cancer 32.9 CCND1 EGFR ERBB2 GSTP1 HRAS PTEN
25 larynx cancer 32.7 CCND1 CDKN2A EGFR GSTP1 TP53
26 lung cancer 32.5 BRAF CCND1 CDKN2A DDR2 DLEC1 EGFR
27 papilloma 32.2 CCND1 CDKN2A PTEN RB1 TP53 TP63
28 oral leukoplakia 32.1 CDKN2A ERBB2 TP53
29 basal cell carcinoma 32.1 CCND1 CDKN2A PTEN TP53 TP63
30 inverted papilloma 31.9 CDKN2A SERPINB3 TP53
31 melanoma 31.7 BRAF CCND1 CDKN2A HRAS PTEN TP53
32 cervical cancer 31.7 CDKN2A HRAS PTGS2 RB1 SERPINB3 SERPINB4
33 small cell cancer of the lung 31.6 CDKN2A EGFR RB1 TP53
34 small cell carcinoma 31.6 EGFR PTEN TP53
35 bowenoid papulosis 31.5 CCND1 CDKN2A PTGS2
36 retinoblastoma 31.5 CCND1 CDKN2A RB1 TP53
37 cervical adenocarcinoma 31.5 CDKN2A EGFR ERBB2 PTGS2 TP53
38 suppressor of tumorigenicity 3 31.4 CDKN2A RB1 TP53
39 adenoma 31.4 BRAF CCND1 PTGS2 TGFBR2 TP53
40 pleomorphic adenoma 31.3 ERBB2 TP53 TP63
41 transitional cell carcinoma 31.3 EGFR ERBB2 PTGS2 TP53
42 thyroid cancer, nonmedullary, 1 31.2 BRAF CCND1 HRAS PTEN
43 gastric cardia adenocarcinoma 31.2 TGFBR2 TP53 WWOX
44 tongue cancer 31.2 CCND1 CDKN2A TP53
45 balanitis xerotica obliterans 31.2 CCND1 CDKN2A PTGS2 TP53
46 in situ carcinoma 31.2 CDKN2A EGFR ERBB2 TP53
47 barrett's adenocarcinoma 31.2 CDKN2A ERBB2 PTGS2 TP53
48 necrotizing sialometaplasia 31.2 CDKN2A TP53 TP63
49 skin melanoma 31.1 BRAF CDKN2A PTGS2 TP53
50 sarcoma 31.1 BRAF HRAS RB1 TP53

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma:



Diseases related to Squamous Cell Carcinoma

Symptoms & Phenotypes for Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

25 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.6 HRAS EGFR BRAF
2 Decreased viability GR00107-A-1 10.6 TGFBR2
3 Decreased viability GR00221-A-1 10.6 CDKN2A HRAS DDR2 TGFBR2 DLEC1 EGFR
4 Decreased viability GR00221-A-2 10.6 HRAS DDR2 DLEC1
5 Decreased viability GR00221-A-3 10.6 ERBB2 CDKN2A HRAS TGFBR2
6 Decreased viability GR00221-A-4 10.6 CDKN2A DDR2 TGFBR2 EGFR BRAF ERBB2
7 Decreased viability GR00301-A 10.6 BRAF
8 Decreased viability GR00381-A-1 10.6 BRAF
9 Decreased viability in esophageal squamous lineage GR00235-A 10 TP63 ERBB2 CDKN2A HRAS PTEN DDR2
10 Increased cell death HMECs cells GR00103-A-0 9.63 GSTP1 WWOX PTEN TGFBR2 EGFR TP53
11 Decreased cella89culturea89derived Hepatitis C virus (HCVcc GR00234-A-2 9.54 DDR2 BRAF EGFR
12 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 WWOX CDKN2A PTEN RB1 TP53
13 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 WWOX CDKN2A PTEN RB1 BRAF TP53
14 Increased cell viability after pRB stimulation GR00230-A-1 9.26 ERBB2 DDR2 TGFBR2 EGFR

MGI Mouse Phenotypes related to Squamous Cell Carcinoma:

43 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.47 RB1 PTGS2 TP53 TGFBR2 EGFR DDR2
2 cellular MP:0005384 10.46 RB1 PTGS2 TP53 TGFBR2 CTTN BRAF
3 growth/size/body region MP:0005378 10.46 RB1 PTGS2 TP53 TGFBR2 BRAF EGFR
4 endocrine/exocrine gland MP:0005379 10.44 RB1 PTGS2 TGFBR2 TP53 EGFR DDR2
5 behavior/neurological MP:0005386 10.41 PTEN PTGS2 TP53 TGFBR2 RB1 CCND1
6 homeostasis/metabolism MP:0005376 10.41 PTGS2 PTEN TP53 TGFBR2 RB1 CCND1
7 mortality/aging MP:0010768 10.39 RB1 PTGS2 PTEN TP53 TGFBR2 CTTN
8 digestive/alimentary MP:0005381 10.38 RB1 PTGS2 TGFBR2 TP53 EGFR CDKN2A
9 immune system MP:0005387 10.37 RB1 PTGS2 PTEN SERPINB4 TP53 TGFBR2
10 embryo MP:0005380 10.34 RB1 PTGS2 PTEN TP53 TGFBR2 CTTN
11 integument MP:0010771 10.33 RB1 PTGS2 TP53 EGFR DDR2 CDKN2A
12 hematopoietic system MP:0005397 10.32 PTEN PTGS2 TGFBR2 RB1 CCND1 CTTN
13 neoplasm MP:0002006 10.32 PTGS2 RB1 TGFBR2 TP53 CDKN2A DDR2
14 craniofacial MP:0005382 10.31 RB1 TP53 TGFBR2 EGFR DDR2 CCND1
15 nervous system MP:0003631 10.27 RB1 PTGS2 PTEN TP53 TGFBR2 CCND1
16 muscle MP:0005369 10.24 RB1 PTGS2 TP53 TGFBR2 EGFR DDR2
17 adipose tissue MP:0005375 10.23 PTGS2 PTEN TP53 TGFBR2 RB1 BRAF
18 liver/biliary system MP:0005370 10.18 PTGS2 PTEN TP53 TGFBR2 RB1 BRAF
19 no phenotypic analysis MP:0003012 10.17 RB1 PTGS2 TP53 SART1 EGFR DDR2
20 normal MP:0002873 10.14 RB1 PTGS2 PTEN TP53 TGFBR2 BRAF
21 reproductive system MP:0005389 10.1 RB1 PTGS2 TP53 DDR2 CDKN2A CCND1
22 limbs/digits/tail MP:0005371 10.08 PTEN RB1 DDR2 TP63 TP53 ERBB2
23 respiratory system MP:0005388 10 RB1 PTGS2 TGFBR2 TP53 SERPINB4 CDKN2A
24 renal/urinary system MP:0005367 9.92 PTEN PTGS2 RB1 BRAF TP63 TP53
25 pigmentation MP:0001186 9.85 PTEN TP53 RB1 BRAF CDKN2A EGFR
26 skeleton MP:0005390 9.8 RB1 PTGS2 TGFBR2 TP53 DDR2 CDKN2A
27 vision/eye MP:0005391 9.36 RB1 PTGS2 TP53 TGFBR2 EGFR DDR2

Drugs & Therapeutics for Squamous Cell Carcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Erbitux 17 45 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
2
Intron A 17 45 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
3
Taxotere 17 45 DOCETAXEL Rhone Poulenc Rorer May 1996

Drugs for Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 567)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 205923-56-4 56842117 2333
2
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
3
Ethanol Approved Phase 4,Phase 1 64-17-5 702
4
Petrolatum Approved, Investigational Phase 4 8009-03-8
5 Titanium dioxide Approved Phase 4 13463-67-7
6
Imiquimod Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99011-02-6 57469
7
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 38904 498142
8
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 2767 441203 84093
9
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 184475-35-2 123631
10
Pemetrexed Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 150399-23-8, 137281-23-3 60843 446556
11
Nedaplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 95734-82-0
12
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154361-50-9 60953
13
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
14
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
15
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
16
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
17
Cevimeline Approved Phase 4,Phase 3 107233-08-9 25137844 83898
18
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
19
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
20
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
21
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
22
Tacrolimus Approved, Investigational Phase 4,Phase 3 104987-11-3 445643 439492
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
24
Acitretin Approved Phase 4,Phase 2 55079-83-9 5284513 6437841
25
Raltitrexed Approved, Investigational Phase 4,Phase 3 112887-68-0 104758
26
Morphine Approved, Investigational Phase 4 57-27-2 5288826
27
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
28
Azathioprine Approved Phase 4 446-86-6 2265
29
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
30
Mycophenolic acid Approved Phase 4 24280-93-1 446541
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
32
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
33
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 68-26-8, 11103-57-4 445354
34
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 114977-28-5 148124 9877265
35
Camptothecin Experimental Phase 4,Phase 3,Phase 2,Phase 1 7689-03-4
36 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
39 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
41 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Mitomycins Phase 4,Phase 3,Phase 2,Phase 1
43 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Anti-Allergic Agents Phase 4,Phase 2
45 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
46 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 mometasone furoate Phase 4
48 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1
49 Interferon Inducers Phase 4,Phase 2,Phase 3,Phase 1
50 interferons Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 2005)

# Name Status NCT ID Phase Drugs
1 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
2 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
3 A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4 placebo;Sodium Glycididazole
4 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
5 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
6 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
7 Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
8 Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Completed NCT00868088 Phase 4
9 Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy Completed NCT02972216 Phase 4 Nolbaxol;Taxotere;cisplatin
10 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
11 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4 docetaxel and cisplatin
12 An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck Completed NCT00684385 Phase 4 ZD1839
13 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4 Cevimeline
14 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
15 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
16 Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients Completed NCT02622880 Phase 4
17 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
18 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
19 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
20 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
21 A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients Completed NCT01283906 Phase 4
22 Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Recruiting NCT02513342 Phase 4 Docetaxel;Cisplatin
23 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. Recruiting NCT03196843 Phase 4 Raltitrexed
24 Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Recruiting NCT02869321 Phase 4 Fentanyl;Morphine Sulfate;Fentanyl placebo;Morphine Sulfate placebo
25 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
26 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
27 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Active, not recruiting NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
28 Lipusu Advanced Squamous Cell Carcinoma of Lung Study Carboplatin in Advanced Squamous Cell Carcinoma of Lung Not yet recruiting NCT02996214 Phase 4 Paclitaxel Liposome;Gemcitabine;Cisplatin
29 Acitretin Plasma Levels Under Hemodialysis Suspended NCT00488384 Phase 4 Chemopreventive application (Acitretin)
30 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
31 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
32 Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Withdrawn NCT01663558 Phase 4 imiquimod
33 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
34 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3 Aspirin
35 Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma Unknown status NCT01752205 Phase 3 Paclitaxel;Erlotinib
36 Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 Unknown status NCT01398449 Phase 3
37 E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
38 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
39 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
40 Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment Unknown status NCT00935675 Phase 3 Escitalopram
41 Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
42 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
43 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
44 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
45 Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3 cisplatin;fluorouracil
46 Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate Unknown status NCT00041613 Phase 3
47 Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Unknown status NCT00041626 Phase 3
48 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial Unknown status NCT02319187 Phase 3 S1;S-1;irinotecan
49 Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer. Unknown status NCT01124409 Phase 3
50 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine

Search NIH Clinical Center for Squamous Cell Carcinoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: neoplasms, squamous cell

Genetic Tests for Squamous Cell Carcinoma

Genetic tests related to Squamous Cell Carcinoma:

# Genetic test Affiliating Genes
1 Squamous Cell Carcinoma 28
2 Squamous Cell Carcinoma of the Skin 28

Anatomical Context for Squamous Cell Carcinoma

MalaCards organs/tissues related to Squamous Cell Carcinoma:

38
Lung, Skin, Tongue, Lymph Node, Cervix, Endothelial, T Cells

Publications for Squamous Cell Carcinoma

Articles related to Squamous Cell Carcinoma:

(show top 50) (show all 12224)
# Title Authors Year
1
Proliferative Index in Invasive Tumor Front of Oral Squamous Cell Carcinoma: A Potential Prognostic Indicator. ( 29422466 )
2018
2
Oral mucosa tissue gene expression profiling before, during, and after radiation therapy for tonsil squamous cell carcinoma. ( 29338018 )
2018
3
Identification of a progression-associated long non-coding RNA signature for predicting the prognosis of lung squamous cell carcinoma. ( 29434705 )
2018
4
Locally advanced oral squamous cell carcinoma patients treated with photobiomodulation for prevention of oral mucositis: retrospective outcomes and safety analyses. ( 29423682 )
2018
5
Hypertrophic Lichen Planus and Well-Differentiated Squamous Cell Carcinoma: A Diagnostic Conundrum. ( 29360655 )
2018
6
Vulvar intraepithelial neoplasia and vulvar squamous cell carcinoma: differential dermoscopic features in a case series, and a progression model. ( 29315730 )
2018
7
Tumor budding as a novel predictor of occult metastasis in cT2N0 tongue squamous cell carcinoma. ( 29307623 )
2018
8
Risk factors for positive margins after wide local excision of cutaneous squamous cell carcinoma. ( 29448853 )
2018
9
Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma. ( 29050985 )
2018
10
Gene expression analyses associated with malignant phenotypes of metastatic sub-clones derived from a mouse oral squamous cell carcinoma Sq-1979 cell line. ( 29435078 )
2018
11
Expression of Nemo-like kinase in cervical squamous cell carcinoma: a clinicopathological study. ( 29445289 )
2018
12
Overexpression of F-box only protein 31 predicts poor prognosis and deregulates p38I+- and JNK-mediated apoptosis in esophageal squamous cell carcinoma. ( 28905993 )
2018
13
Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy. ( 28975226 )
2018
14
Salvage Surgery for Locoregional Failure in Anal Squamous Cell Carcinoma. ( 29337772 )
2018
15
Predictive biomarkers and EGFR inhibitors in squamous cell carcinoma of head and neck (SCCHN). ( 29444313 )
2018
16
Postoperative Radiotherapy for Oral Squamous Cell Carcinoma With Histologic Risk Factors: Are We Over-Treating? ( 29438656 )
2018
17
Association of an intact E2 gene with higher HPV viral load, higher viral oncogene expression, and improved clinical outcome in HPV16 positive head and neck squamous cell carcinoma. ( 29451891 )
2018
18
Oral leukoplakia, a precancerous lesion of squamous cell carcinoma, in patients with long-term pegylated liposomal doxorubicin treatment. ( 29443777 )
2018
19
Squamous Cell Carcinoma of the Gingiva Mimicking Periodontal Disease: A Diagnostic Challenge and Therapeutic Dilemma. ( 29447319 )
2018
20
Fungating Growth of Squamous Cell Carcinoma in Long-Standing Meningocele. ( 29393254 )
2018
21
Meta-analysis of the prognostic value of the neutrophil-to-lymphocyte ratio in oral squamous cell carcinoma. ( 29406591 )
2018
22
Features Causing Confusion between Basal Cell Carcinoma and Squamous Cell Carcinoma in Clinical Diagnosis. ( 29386834 )
2018
23
Reply to 'Comment on 'Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis". ( 29449674 )
2018
24
Epithelial mesenchymal transition induced by the CXCL9/CXCR3 axis through AKT activation promotes invasion and metastasis in tongue squamous cell carcinoma. ( 29286143 )
2018
25
Downregulation of matrix metalloproteinase 14 by the antitumor miRNA, miR-150-5p, inhibits the aggressiveness of lung squamous cell carcinoma cells. ( 29286099 )
2018
26
Proteomic Analysis of Secretomes of Oncolytic Herpes Simplex Virus-Infected Squamous Cell Carcinoma Cells. ( 29360750 )
2018
27
Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx. ( 29073727 )
2018
28
Pediatric head and neck squamous cell carcinoma: Patient demographics, treatment trends and outcomes. ( 29447885 )
2018
29
MicroRNA-492 overexpression involves in cell proliferation, migration, and radiotherapy response of cervical squamous cell carcinomas. ( 28802022 )
2018
30
FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting I^-catenin through mRNA demethylation. ( 29315835 )
2018
31
Unusual Multinucleated Giant Cell Reaction in a Tongue Squamous Cell Carcinoma: Histopathological and Immunohistochemical Features. ( 29427031 )
2018
32
Adipose-derived stem cell conditioned medium attenuates cisplatin-triggered apoptosis in tongue squamous cell carcinoma. ( 29207154 )
2018
33
Serum bilirubin level predicts post-operative overall survival in oral squamous cell carcinoma. ( 29430757 )
2018
34
Complex Reconstruction with Flaps After Abdominoperineal Resection and Groin Dissection for Anal Squamous Cell Carcinoma: A Difficult Case Involving Many Specialities. ( 29339717 )
2018
35
CDKN1A-interacting zinc finger protein 1 is a novel biomarker for lung squamous cell carcinoma. ( 29285191 )
2018
36
Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR. ( 29394946 )
2018
37
Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma. ( 29384143 )
2018
38
Mecambridine induces potent cytotoxic effects, autophagic cell death and modulation of the mTOR/PI3K/Akt signaling pathway in HSC-3 oral squamous cell carcinoma cells. ( 29422960 )
2018
39
Negative regulation of lncRNA GAS5 by miR-196a inhibits esophageal squamous cell carcinoma growth. ( 29170131 )
2018
40
MicroRNA-196a-5p is a potential prognostic marker of delayed lymph node metastasis in early-stage tongue squamous cell carcinoma. ( 29434944 )
2018
41
A novel multiplex detection array revealed systemic complement activation in oral squamous cell carcinoma. ( 29423024 )
2018
42
Case of primary cutaneous anaplastic large cell lymphoma misdiagnosed as squamous cell carcinoma by pseudocarcinomatous hyperplasia. ( 29314194 )
2018
43
Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. ( 29296096 )
2018
44
Secretory leukocyte peptidase inhibitor expression and apoptosis effect in oral leukoplakia and oral squamous cell carcinoma. ( 29436667 )
2018
45
Global Quantitative Proteomics reveal Deregulation of Cytoskeletal and Apoptotic Signalling Proteins in Oral Tongue Squamous Cell Carcinoma. ( 29371635 )
2018
46
Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. ( 29318765 )
2018
47
Association between genetic polymorphisms in the promoters of let-7 and risk of cervical squamous cell carcinoma. ( 29154871 )
2018
48
MiRNA373 induces cervical squamous cell carcinoma SiHa cell apoptosis. ( 29125482 )
2018
49
Expression of I^1integrin in normal epithelium, oral submucous fibrosis and oral squamous cell carcinoma. ( 29113685 )
2018
50
Prognostic Significance of Human Papilloma Virus and p16 Expression in Patients with Vulvar Squamous Cell Carcinoma who Received Radiotherapy. ( 29449057 )
2018

Variations for Squamous Cell Carcinoma

ClinVar genetic disease variations for Squamous Cell Carcinoma:

6 (show all 24)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
3 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
4 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
5 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
6 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
7 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
8 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
9 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
10 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
11 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
12 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
13 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
14 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
15 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
16 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
17 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
18 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
19 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
20 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
21 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
22 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic/Likely pathogenic rs876659802 GRCh37 Chromosome 17, 7577105: 7577105
23 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
24 DDR2 NM_001014796.2(DDR2): c.2304T> A (p.Ser768Arg) single nucleotide variant Pathogenic rs267598140 GRCh37 Chromosome 1, 162748390: 162748390

Cosmic variations for Squamous Cell Carcinoma:

9 (show top 50) (show all 646)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10726 TP53 skin,face,carcinoma,squamous cell carcinoma c.856G>A p.E286K 35
2 COSM10656 TP53 skin,face,carcinoma,squamous cell carcinoma c.742C>T p.R248W 35
3 COSM43665 TP53 skin,face,carcinoma,squamous cell carcinoma c.746G>C p.R249T 35
4 COSM10988 TP53 skin,face,carcinoma,squamous cell carcinoma c.772G>A p.E258K 35
5 COSM44225 TP53 skin,arm,carcinoma,squamous cell carcinoma c.859G>A p.E287K 35
6 COSM43588 TP53 skin,face,carcinoma,squamous cell carcinoma c.740A>C p.N247T 35
7 COSM11081 TP53 skin,face,carcinoma,squamous cell carcinoma c.733G>T p.G245C 35
8 COSM10733 TP53 skin,face,carcinoma,squamous cell carcinoma c.574C>T p.Q192* 35
9 COSM17489 PTCH1 skin,face,carcinoma,squamous cell carcinoma c.3724G>A p.E1242K 35
10 COSM585 NRAS skin,face,carcinoma,squamous cell carcinoma c.183A>T p.Q61H 35
11 COSM574 NRAS skin,face,carcinoma,squamous cell carcinoma c.38G>T p.G13V 35
12 COSM564 NRAS skin,face,carcinoma,squamous cell carcinoma c.35G>A p.G12D 35
13 COSM520 KRAS skin,face,carcinoma,squamous cell carcinoma c.35G>T p.G12V 35
14 COSM496 HRAS skin,arm,carcinoma,squamous cell carcinoma c.181C>A p.Q61K 35
15 COSM45765 TP53 skin,leg,carcinoma,squamous cell carcinoma c.987C>A p.T329T 34
16 COSM10863 TP53 skin,leg,carcinoma,squamous cell carcinoma c.833C>T p.P278L 34
17 COSM45114 TP53 skin,leg,carcinoma,squamous cell carcinoma c.702C>A p.Y234* 34
18 COSM573 NRAS skin,scalp,carcinoma,squamous cell carcinoma c.38G>A p.G13D 34
19 COSM554 KRAS skin,scalp,carcinoma,squamous cell carcinoma c.183A>C p.Q61H 34
20 COSM499 HRAS skin,trunk,carcinoma,squamous cell carcinoma c.182A>G p.Q61R 34
21 COSM3724309 ZNF536 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1935G>C p.Q645H 30
22 COSM11181 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.764T>C p.I255T 30
23 COSM43565 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.857A>G p.E286G 30
24 COSM43695 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.748C>T p.P250S 30
25 COSM10786 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.949C>T p.Q317* 30
26 COSM44894 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.874A>T p.K292* 30
27 COSM43592 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.395A>T p.K132M 30
28 COSM45615 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.776A>G p.D259G 30
29 COSM10659 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.817C>T p.R273C 30
30 COSM11133 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>C p.C242S 30
31 COSM10646 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>A p.C242Y 30
32 COSM10724 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.839G>C p.R280T 30
33 COSM45248 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.805A>T p.S269C 30
34 COSM10727 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.438G>A p.W146* 30
35 COSM43606 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.734G>A p.G245D 30
36 COSM43635 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.536A>T p.H179L 30
37 COSM44350 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.699C>G p.H233Q 30
38 COSM11063 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.711G>T p.M237I 30
39 COSM11677 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.925C>T p.P309S 30
40 COSM11166 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.406C>T p.Q136* 30
41 COSM10859 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.814G>T p.V272L 30
42 COSM10958 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.797G>T p.G266V 30
43 COSM10758 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 30
44 COSM44821 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.412G>A p.A138T 30
45 COSM44335 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.958A>T p.K320* 30
46 COSM43708 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.422G>A p.C141Y 30
47 COSM43947 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 30
48 COSM45636 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.934A>T p.T312S 30
49 COSM11066 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.578A>T p.H193L 30
50 COSM43564 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.708C>A p.Y236* 30

Copy number variations for Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 98)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13821 1 1 7200000 Copy number TP73 Squamous cell cancer
2 25151 1 184907591 184916179 Amplification PTGS2 Squamous cell cancer
3 31938 1 32200000 39600000 Copy number Squamous cell cancer
4 33706 1 47467454 47552406 Amplification STIL Squamous cell cancer
5 42802 10 40300000 135374737 Copy number Squamous cell cancer
6 49690 11 110000000 134452384 Copy number Squamous cell cancer
7 49993 11 112500000 114500000 Copy number IGSF4 Squamous cell cancer
8 57469 11 63400000 77100000 Copy number GSTP1 Squamous cell cancer
9 57471 11 63400000 77100000 Copy number MEN1 Squamous cell cancer
10 61508 12 1 3100000 Gain LOC440123 Squamous cell cancer
11 61509 12 1 3100000 Gain SLC6A12 Squamous cell cancer
12 61511 12 1 3100000 Gain SLC6A13 Squamous cell cancer
13 61529 12 1 35400000 Copy number Squamous cell cancer
14 61608 12 10000000 12600000 Gain CDKN1B Squamous cell cancer
15 61609 12 10000000 12600000 Gain DKFZP434F0318 Squamous cell cancer
16 66096 12 25249446 25295130 Amplification KRAS Squamous cell cancer
17 66577 12 3100000 5300000 Gain LOC399986 Squamous cell cancer
18 66579 12 3100000 5300000 Gain LOC441627 Squamous cell cancer
19 66581 12 3100000 5300000 Gain TSPAN9 Squamous cell cancer
20 75264 13 18400000 72100000 Copy number Squamous cell cancer
21 77032 13 39500000 46200000 Copy number Squamous cell cancer
22 87575 14 74815283 74818665 Amplification FOS Squamous cell cancer
23 93656 15 57100000 61500000 Loss RORA Squamous cell cancer
24 95697 15 79500000 83000000 Loss DNM1DN11-6 Squamous cell cancer
25 95699 15 79500000 83000000 Loss LOC159170 Squamous cell cancer
26 95701 15 79500000 83000000 Loss LOC161527 Squamous cell cancer
27 95703 15 79500000 83000000 Loss LOC388152 Squamous cell cancer
28 95705 15 79500000 83000000 Loss LOC388160 Squamous cell cancer
29 95707 15 79500000 83000000 Loss LOC440300 Squamous cell cancer
30 95709 15 79500000 83000000 Loss LOC440301 Squamous cell cancer
31 97922 16 14700000 16700000 Loss Squamous cell cancer
32 107539 17 15900000 22100000 Loss Squamous cell cancer
33 111141 17 35097918 35138441 Amplification ERBB2 Squamous cell cancer
34 116535 17 6800000 11200000 Copy number Squamous cell cancer
35 122734 18 59800000 76117153 Copy number Squamous cell cancer
36 123838 18 89115825 89123587 Amplification SPP1 Squamous cell cancer
37 124166 19 1 6900000 Gain BSG Squamous cell cancer
38 124167 19 1 6900000 Gain C19orf19 Squamous cell cancer
39 124168 19 1 6900000 Gain C19orf20 Squamous cell cancer
40 124170 19 1 6900000 Gain CDC34 Squamous cell cancer
41 124171 19 1 6900000 Gain GZMM Squamous cell cancer
42 124173 19 1 6900000 Gain MADCAM1 Squamous cell cancer
43 124175 19 1 6900000 Gain SCHC2 Squamous cell cancer
44 135627 2 118600000 122100000 Gain Squamous cell cancer
45 166091 3 1 3500000 Loss APOD Squamous cell cancer
46 166092 3 1 3500000 Loss CCR2 Squamous cell cancer
47 166093 3 1 3500000 Loss CCRL2 Squamous cell cancer
48 169828 3 14700000 30800000 Copy number Squamous cell cancer
49 171547 3 169200000 172500000 Gain EVI1 Squamous cell cancer
50 171549 3 169200000 172500000 Gain LOC389174 Squamous cell cancer

Expression for Squamous Cell Carcinoma

Search